Jefferies Global Industrials Conference 2026
Logotype for Leidos Holdings Inc

Leidos (LDOS) Jefferies Global Industrials Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Leidos Holdings Inc

Jefferies Global Industrials Conference 2026 summary

9 Sep, 2026

Strategic direction and growth pillars

  • NorthStar 2030 strategy focuses on five growth pillars: defense tech, energy infrastructure, cyber, mission and digital, and managed health services, with recent investments in energy and cyber capabilities.

  • Organic growth is accelerating, with 4% in Q2, 5% in the first half, and guidance raised to 8% for the second half, driven by defense tech, energy, and FAA modernization programs.

  • FAA modernization, including the Common Automation Platform, is a multi-billion dollar opportunity, expected to drive development and sustainment revenues over several years.

  • The IFPC program is scaling production, expected to double output by year-end, with significant growth anticipated in 2027.

  • ENTRUST acquisition doubled the energy business, expanded the addressable market by 3x, and is integrating technology for efficiency and new opportunities.

Segment performance and key programs

  • Health segment remains highly profitable, with the VBA medical disability exam program generating over $1 billion in revenue and strong margins, though incentive payments are paused until year-end.

  • VBA contract recompete may consolidate providers, with Leidos well-positioned due to coverage across all regions and sustained high exam volumes post-PACT Act.

  • MHS GENESIS program continues with a one-year extension; future scope may shift software licensing directly to vendors, but Leidos expects ongoing support and modernization roles.

  • Defense segment grew 6% in the quarter, with a 2.2x book-to-bill ratio, driven by IFPC, ABAD, and new awards in space and maritime unmanned surface vessels.

  • Homeland segment grew 32% (15% organic), supported by FAA, TSA, and international contracts, with margin improvement and further upside expected.

Financial outlook and capital allocation

  • Margins in health are moderating to about 20% in the second half due to incentive suspension, impacting overall company margins, but defense and homeland are expected to drive future margin growth.

  • CapEx for the year was revised down to $250 million, focusing on facility modernization and production capacity, with strong cash flow conversion expected.

  • Integration of ENTRUST is on track, with back office and leadership alignment expected by year-end, and technology adoption driving efficiency.

  • Portfolio strength allows for raised guidance despite health headwinds, with defense tech and energy businesses highlighted as underappreciated growth drivers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more